Abstract:Objective To evaluate the clinical values of promoter methylation of multiple genes in serum for diagnosis of HBV-related hepatocellular carcinoma (HCC). Methods Two milliliters of sera were prepared from each participant including 98 HCC patients, 75 liver cirrhosis (LC) patients, 90 chronic hepatitis B (CHB) patients and 80 healthy controls. BVES, APC, RASSF1A, TIMP3, GSTP1 and HOXA9 were selected as candidate genes. Serum DNA was extracted with magnetic beads and modified by sodium bisulfite treatment. The methylation of the promoters of these genes was measured with MethyLight method. Receiver operating characteristic (ROC) curves were constructed and the areas under the ROC curves (AUCs) were calculated to determine the feasibility of using serum gene methylation as a biomarker for HCC. Results The positive rates of promoter methylation of the 6 genes in serum of the HCC patients were 52.04% for RASSF1A, 36.73% for APC, 29.59% for BVES, 20.41% for HOXA9, 17.35% for GSTP1 and 11.22% for TIMP3. The HCC patients with methylated APC had methylation of RASSF1A as well. The diagnostic performance of serum methylated RASSF1A was superior to that of AFP and the other indicators for the discrimination of the patients with HCC from those with chronic HBV infection. Furthermore, the sensitivity, specificity and AUC of combination of promoter methylation of the 6 genes obviously increased. Conclusions Combined detection of serum BVES, APC, RASSF1A, TIMP3, GSTP1 and HOXA9 promoter methylation could improve the diagnosis of HCC in high-risk population.